{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T02:14:54Z","timestamp":1792721694550,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T00:00:00Z","timestamp":1692230400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T00:00:00Z","timestamp":1692230400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"DOI":"10.1007\/s00296-023-05420-4","type":"journal-article","created":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T16:02:21Z","timestamp":1692288141000},"page":"2099-2106","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Mycophenolate mofetil may be an alternative for maintenance therapy of Beh\u00e7et syndrome uveitis: a single-center retrospective analysis"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3469-7307","authenticated-orcid":false,"given":"Didar","family":"Ucar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5414-7305","authenticated-orcid":false,"given":"Sinem Nihal","family":"Esatoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8263-0692","authenticated-orcid":false,"given":"Emir","family":"Cerme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9729-2577","authenticated-orcid":false,"given":"Bilge","family":"Batu-Oto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6625-1652","authenticated-orcid":false,"given":"Vedat","family":"Hamuryudan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4965-2918","authenticated-orcid":false,"given":"Emire","family":"Seyahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0253-8368","authenticated-orcid":false,"given":"Melike","family":"Melikoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8914-9690","authenticated-orcid":false,"given":"Izzet","family":"Fresko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0555-768X","authenticated-orcid":false,"given":"Y\u0131lmaz","family":"Ozyazgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1952-1135","authenticated-orcid":false,"given":"Gulen","family":"Hatemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,17]]},"reference":[{"key":"5420_CR1","doi-asserted-by":"publisher","first-page":"309","DOI":"10.2147\/JMDH.S93681","volume":"10","author":"SN Esatoglu","year":"2017","unstructured":"Esatoglu SN, Kutlubay Z, Ucar D, Hatemi I, Uygunoglu U, Siva A, Hatemi G (2017) Behcet\u2019s syndrome: providing integrated care. J Multidiscip Healthc 10:309\u2013319. https:\/\/doi.org\/10.2147\/JMDH.S93681","journal-title":"J Multidiscip Healthc"},{"issue":"1","key":"5420_CR2","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1097\/00005792-200301000-00006","volume":"82","author":"E Kural-Seyahi","year":"2003","unstructured":"Kural-Seyahi E, Fresko I, Seyahi N, Ozyazgan Y, Mat C, Hamuryudan V, Yurdakul S, Yazici H (2003) The long-term mortality and morbidity of Behcet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine 82(1):60\u201376. https:\/\/doi.org\/10.1097\/00005792-200301000-00006","journal-title":"Medicine"},{"issue":"1","key":"5420_CR3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1097\/BOR.0000000000000911","volume":"35","author":"I Tugal-Tutkun","year":"2023","unstructured":"Tugal-Tutkun I (2023) Uveitis in Behcet disease\u2014an update. Curr Opin Rheumatol 35(1):17\u201324. https:\/\/doi.org\/10.1097\/BOR.0000000000000911","journal-title":"Curr Opin Rheumatol"},{"issue":"6","key":"5420_CR4","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1136\/annrheumdis-2018-213225","volume":"77","author":"G Hatemi","year":"2018","unstructured":"Hatemi G, Christensen R, Bang D, Bodaghi B, Celik AF, Fortune F, Gaudric J, Gul A, Kotter I, Leccese P, Mahr A, Moots R, Ozguler Y, Richter J, Saadoun D, Salvarani C, Scuderi F, Sfikakis PP, Siva A, Stanford M, Tugal-Tutkun I, West R, Yurdakul S, Olivieri I, Yazici H (2018) 2018 update of the EULAR recommendations for the management of Behcet\u2019s syndrome. Ann Rheum Dis 77(6):808\u2013818. https:\/\/doi.org\/10.1136\/annrheumdis-2018-213225","journal-title":"Ann Rheum Dis"},{"key":"5420_CR5","doi-asserted-by":"publisher","first-page":"618973","DOI":"10.3389\/fimmu.2020.618973","volume":"11","author":"SN Esatoglu","year":"2020","unstructured":"Esatoglu SN, Akkoc-Mustafayev FN, Ozguler Y, Ozbakir F, Nohut OK, Cevirgen D, Hamuryudan V, Hatemi I, Celik AF, Yazici H, Hatemi G (2020) Immunogenicity of infliximab among patients with Behcet syndrome: a controlled study. Front Immunol 11:618973. https:\/\/doi.org\/10.3389\/fimmu.2020.618973","journal-title":"Front Immunol"},{"issue":"2","key":"5420_CR6","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1080\/14656566.2022.2155047","volume":"24","author":"Y Ozguler","year":"2023","unstructured":"Ozguler Y, Esatoglu SN, Hatemi G (2023) Current pharmacological solutions for Behcet\u2019s syndrome. Expert Opin Pharmacother 24(2):221\u2013231. https:\/\/doi.org\/10.1080\/14656566.2022.2155047","journal-title":"Expert Opin Pharmacother"},{"issue":"12","key":"5420_CR7","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1093\/rheumatology\/key242","volume":"57","author":"Y Ozguler","year":"2018","unstructured":"Ozguler Y, Leccese P, Christensen R, Esatoglu SN, Bang D, Bodaghi B, Celik AF, Fortune F, Gaudric J, Gul A, Kotter I, Mahr A, Moots RJ, Richter J, Saadoun D, Salvarani C, Scuderi F, Sfikakis PP, Siva A, Stanford M, Tugal-Tutkun I, West R, Yurdakul S, Olivieri I, Yazici H, Hatemi G (2018) Management of major organ involvement of Behcet\u2019s syndrome: a systematic review for update of the EULAR recommendations. Rheumatology 57(12):2200\u20132212. https:\/\/doi.org\/10.1093\/rheumatology\/key242","journal-title":"Rheumatology"},{"issue":"5","key":"5420_CR8","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1681\/ASN.2008101028","volume":"20","author":"GB Appel","year":"2009","unstructured":"Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, Li LS, Mysler E, Sanchez-Guerrero J, Solomons N, Wofsy D, Aspreva Lupus Management Study G (2009) Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 20(5):1103\u20131112. https:\/\/doi.org\/10.1681\/ASN.2008101028","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"5420_CR9","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1136\/annrheumdis-2016-210882","volume":"76","author":"J Ordi-Ros","year":"2017","unstructured":"Ordi-Ros J, Saez-Comet L, Perez-Conesa M, Vidal X, Mitjavila F, Castro Salomo A, Cuquet Pedragosa J, Ortiz-Santamaria V, Mauri Plana M, Cortes-Hernandez J (2017) Enteric-coated mycophenolate sodium versus azathioprine in patients with active systemic lupus erythematosus: a randomised clinical trial. Ann Rheum Dis 76(9):1575\u20131582. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210882","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"5420_CR10","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1136\/annrheumdis-2018-214245","volume":"78","author":"RB Jones","year":"2019","unstructured":"Jones RB, Hiemstra TF, Ballarin J, Blockmans DE, Brogan P, Bruchfeld A, Cid MC, Dahlsveen K, de Zoysa J, Espigol-Frigole G, Lanyon P, Peh CA, Tesar V, Vaglio A, Walsh M, Walsh D, Walters G, Harper L, Jayne D, European Vasculitis Study G (2019) Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial. Ann Rheum Dis 78(3):399\u2013405. https:\/\/doi.org\/10.1136\/annrheumdis-2018-214245","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"5420_CR11","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","volume":"4","author":"DP Tashkin","year":"2016","unstructured":"Tashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC, Goldin J, Arriola E, Volkmann ER, Kafaja S, Silver R, Steen V, Strange C, Wise R, Wigley F, Mayes M, Riley DJ, Hussain S, Assassi S, Hsu VM, Patel B, Phillips K, Martinez F, Golden J, Connolly MK, Varga J, Dematte J, Hinchcliff ME, Fischer A, Swigris J, Meehan R, Theodore A, Simms R, Volkov S, Schraufnagel DE, Scholand MB, Frech T, Molitor JA, Highland K, Read CA, Fritzler MJ, Kim GHJ, Tseng CH, Elashoff RM, Sclerodema Lung Study III (2016) Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med 4(9):708\u2013719. https:\/\/doi.org\/10.1016\/S2213-2600(16)30152-7","journal-title":"Lancet Respir Med"},{"issue":"10","key":"5420_CR12","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1001\/jama.2019.12618","volume":"322","author":"SR Rathinam","year":"2019","unstructured":"Rathinam SR, Gonzales JA, Thundikandy R, Kanakath A, Murugan SB, Vedhanayaki R, Lim LL, Suhler EB, Al-Dhibi HA, Doan T, Keenan JD, Rao MM, Ebert CD, Nguyen HH, Kim E, Porco TC, Acharya NR, Group FR (2019) Effect of corticosteroid-sparing treatment with mycophenolate mofetil vs methotrexate on inflammation in patients with uveitis: a randomized clinical trial. JAMA 322(10):936\u2013945. https:\/\/doi.org\/10.1001\/jama.2019.12618","journal-title":"JAMA"},{"issue":"9","key":"5420_CR13","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1111\/ped.13943","volume":"61","author":"S Terashita","year":"2019","unstructured":"Terashita S, Tanaka T, Taneichi H, Adachi Y, Mori M (2019) Mycophenolate mofetil and prednisolone for cerebral sinus venous thrombosis with Behcet\u2019s disease. Pediatr Int 61(9):920\u2013922. https:\/\/doi.org\/10.1111\/ped.13943","journal-title":"Pediatr Int"},{"issue":"4 Suppl 67","key":"5420_CR14","first-page":"S64","volume":"29","author":"E Shugaiv","year":"2011","unstructured":"Shugaiv E, Tuzun E, Mutlu M, Kiyat-Atamer A, Kurtuncu M, Akman-Demir G (2011) Mycophenolate mofetil as a novel immunosuppressant in the treatment of neuro-Behcet\u2019s disease with parenchymal involvement: presentation of four cases. Clin Exp Rheumatol 29(4 Suppl 67):S64-67","journal-title":"Clin Exp Rheumatol"},{"issue":"7","key":"5420_CR15","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1111\/j.1365-4632.2010.04505.x","volume":"50","author":"O Kose","year":"2011","unstructured":"Kose O, Simsek I, Pay S (2011) Mycophenolate sodium in the treatment of mucocutaneous Behcet\u2019s diseases. Int J Dermatol 50(7):895\u2013896. https:\/\/doi.org\/10.1111\/j.1365-4632.2010.04505.x","journal-title":"Int J Dermatol"},{"issue":"4","key":"5420_CR16","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1159\/000051781","volume":"203","author":"YD Adler","year":"2001","unstructured":"Adler YD, Mansmann U, Zouboulis CC (2001) Mycophenolate mofetil is ineffective in the treatment of mucocutaneous Adamantiades-Behcet\u2019s disease. Dermatology 203(4):322\u2013324. https:\/\/doi.org\/10.1159\/000051781","journal-title":"Dermatology"},{"issue":"3","key":"5420_CR17","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","volume":"140","author":"DA Jabs","year":"2005","unstructured":"Jabs DA, Nussenblatt RB, Rosenbaum JT, Standardization of Uveitis Nomenclature Working G (2005) Standardization of uveitis nomenclature for reporting clinical data results of the first international workshop. Am J Ophthalmol 140(3):509\u2013516. https:\/\/doi.org\/10.1016\/j.ajo.2005.03.057","journal-title":"Am J Ophthalmol"},{"issue":"8697","key":"5420_CR18","first-page":"1078","volume":"335","author":"International Study Group for Behcet\u2019s Disease","year":"1990","unstructured":"International Study Group for Behcet\u2019s Disease (1990) Criteria for diagnosis of Behcet\u2019s disease. International study group for Behcet\u2019s Disease. Lancet 335(8697):1078\u20131080","journal-title":"Lancet"},{"issue":"3","key":"5420_CR19","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1007\/s12016-014-8425-z","volume":"49","author":"Y Ozyazgan","year":"2015","unstructured":"Ozyazgan Y, Ucar D, Hatemi G, Yazici Y (2015) Ocular involvement of behcet\u2019s syndrome: a comprehensive review. Clin Rev Allergy Immunol 49(3):298\u2013306. https:\/\/doi.org\/10.1007\/s12016-014-8425-z","journal-title":"Clin Rev Allergy Immunol"},{"issue":"5","key":"5420_CR20","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1056\/NEJM199002013220501","volume":"322","author":"H Yazici","year":"1990","unstructured":"Yazici H, Pazarli H, Barnes CG, Tuzun Y, Ozyazgan Y, Silman A, Serdaroglu S, Oguz V, Yurdakul S, Lovatt GE et al (1990) A controlled trial of azathioprine in Behcet\u2019s syndrome. N Engl J Med 322(5):281\u2013285. https:\/\/doi.org\/10.1056\/NEJM199002013220501","journal-title":"N Engl J Med"},{"issue":"12","key":"5420_CR21","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1002\/acr.20308","volume":"62","author":"D Saadoun","year":"2010","unstructured":"Saadoun D, Wechsler B, Terrada C, Hajage D, Le Thi HD, Resche-Rigon M, Cassoux N, Le Hoang P, Amoura Z, Bodaghi B, Cacoub P (2010) Azathioprine in severe uveitis of Behcet\u2019s disease. Arthritis Care Res 62(12):1733\u20131738. https:\/\/doi.org\/10.1002\/acr.20308","journal-title":"Arthritis Care Res"},{"issue":"4","key":"5420_CR22","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1136\/bjo.76.4.241","volume":"76","author":"Y Ozyazgan","year":"1992","unstructured":"Ozyazgan Y, Yurdakul S, Yazici H, Tuzun B, Iscimen A, Tuzun Y, Aktunc T, Pazarli H, Hamuryudan V, Muftuoglu A (1992) Low dose cyclosporin A versus pulsed cyclophosphamide in Behcet\u2019s syndrome: a single masked trial. Br J Ophthalmol 76(4):241\u2013243. https:\/\/doi.org\/10.1136\/bjo.76.4.241","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"5420_CR23","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s11739-019-02046-y","volume":"14","author":"E Seyahi","year":"2019","unstructured":"Seyahi E (2019) Phenotypes in Behcet\u2019s syndrome. Intern Emerg Med 14(5):677\u2013689. https:\/\/doi.org\/10.1007\/s11739-019-02046-y","journal-title":"Intern Emerg Med"},{"issue":"1","key":"5420_CR24","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1186\/s12886-018-0929-5","volume":"18","author":"H Celiker","year":"2018","unstructured":"Celiker H, Kazokoglu H, Direskeneli H (2018) Conventional immunosuppressive therapy in severe Behcet\u2019s uveitis: the switch rate to the biological agents. BMC Ophthalmol 18(1):261. https:\/\/doi.org\/10.1186\/s12886-018-0929-5","journal-title":"BMC Ophthalmol"},{"issue":"12","key":"5420_CR25","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1093\/rheumatology\/keu266","volume":"53","author":"V Calvo-Rio","year":"2014","unstructured":"Calvo-Rio V, Blanco R, Beltran E, Sanchez-Burson J, Mesquida M, Adan A, Hernandez MV, Hernandez Garfella M, Valls Pascual E, Martinez-Costa L, Sellas-Fernandez A, Cordero Coma M, Diaz-Llopis M, Gallego R, Salom D, Garcia Serrano JL, Ortego N, Herreras JM, Fonollosa A, Garcia-Aparicio AM, Maiz O, Blanco A, Torre I, Fernandez-Espartero C, Jovani V, Peiteado-Lopez D, Pato E, Cruz J, Fernandez-Cid C, Aurrecoechea E, Garcia M, Caracuel MA, Montilla C, Atanes A, Hernandez FF, Insua S, Gonzalez-Suarez S, Sanchez-Andrade A, Gamero F, Linares L, Romero-Bueno F, Garcia AJ, Almodovar R, Minguez E, Carrasco Cubero C, Olive A, Vazquez J, Ruiz Moreno O, Jimenez-Zorzo F, Manero J, Munoz Fernandez S, Rueda-Gotor J, Gonzalez-Gay MA (2014) Anti-TNF-alpha therapy in patients with refractory uveitis due to Behcet\u2019s disease: a 1-year follow-up study of 124 patients. Rheumatology 53(12):2223\u20132231. https:\/\/doi.org\/10.1093\/rheumatology\/keu266","journal-title":"Rheumatology"},{"issue":"3","key":"5420_CR26","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.ophtha.2009.08.010","volume":"117","author":"RO Kacmaz","year":"2010","unstructured":"Kacmaz RO, Kempen JH, Newcomb C, Daniel E, Gangaputra S, Nussenblatt RB, Rosenbaum JT, Suhler EB, Thorne JE, Jabs DA, Levy-Clarke GA, Foster CS (2010) Cyclosporine for ocular inflammatory diseases. Ophthalmology 117(3):576\u2013584. https:\/\/doi.org\/10.1016\/j.ophtha.2009.08.010","journal-title":"Ophthalmology"},{"issue":"4","key":"5420_CR27","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.ajo.2009.05.008","volume":"148","author":"S Pasadhika","year":"2009","unstructured":"Pasadhika S, Kempen JH, Newcomb CW, Liesegang TL, Pujari SS, Rosenbaum JT, Thorne JE, Foster CS, Jabs DA, Levy-Clarke GA, Nussenblatt RB, Suhler EB (2009) Azathioprine for ocular inflammatory diseases. Am J Ophthalmol 148(4):500-509 e502. https:\/\/doi.org\/10.1016\/j.ajo.2009.05.008","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"5420_CR28","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.ajo.2009.09.026","volume":"149","author":"E Daniel","year":"2010","unstructured":"Daniel E, Thorne JE, Newcomb CW, Pujari SS, Kacmaz RO, Levy-Clarke GA, Nussenblatt RB, Rosenbaum JT, Suhler EB, Foster CS, Jabs DA, Kempen JH (2010) Mycophenolate mofetil for ocular inflammation. Am J Ophthalmol 149(3):423-432 e421-422. https:\/\/doi.org\/10.1016\/j.ajo.2009.09.026","journal-title":"Am J Ophthalmol"},{"issue":"11","key":"5420_CR29","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1016\/j.ophtha.2009.04.020","volume":"116","author":"S Gangaputra","year":"2009","unstructured":"Gangaputra S, Newcomb CW, Liesegang TL, Kacmaz RO, Jabs DA, Levy-Clarke GA, Nussenblatt RB, Rosenbaum JT, Suhler EB, Thorne JE, Foster CS, Kempen JH, Systemic Immunosuppressive Therapy for Eye Diseases Cohort S (2009) Methotrexate for ocular inflammatory diseases. Ophthalmology. 116(11):2188-2198 e2181. https:\/\/doi.org\/10.1016\/j.ophtha.2009.04.020","journal-title":"Ophthalmology."},{"issue":"12","key":"5420_CR30","doi-asserted-by":"publisher","first-page":"3213","DOI":"10.1111\/j.1572-0241.2008.02161_13.x","volume":"103","author":"JH Kappen","year":"2008","unstructured":"Kappen JH, Mensink PB, Lesterhuis W, Lachman S, van Daele PL, van Hagen PM, van Laar JA (2008) Mycophenolate sodium: effective treatment for therapy-refractory intestinal Behcet\u2019s disease, evaluated with enteroscopy. Am J Gastroenterol 103(12):3213\u20133214. https:\/\/doi.org\/10.1111\/j.1572-0241.2008.02161_13.x","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"5420_CR31","doi-asserted-by":"publisher","first-page":"22227","DOI":"10.1038\/s41598-020-78718-z","volume":"10","author":"N Horiguchi","year":"2020","unstructured":"Horiguchi N, Kamoi K, Horie S, Iwasaki Y, Kurozumi-Karube H, Takase H, Ohno-Matsui K (2020) A 10-year follow-up of infliximab monotherapy for refractory uveitis in Behcet\u2019s syndrome. Sci Rep 10(1):22227. https:\/\/doi.org\/10.1038\/s41598-020-78718-z","journal-title":"Sci Rep"},{"key":"5420_CR32","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jaut.2015.06.005","volume":"62","author":"H Vallet","year":"2015","unstructured":"Vallet H, Riviere S, Sanna A, Deroux A, Moulis G, Addimanda O, Salvarani C, Lambert M, Bielefeld P, Seve P, Sibilia J, Pasquali J, Fraison J, Marie I, Perard L, Bouillet L, Cohen F, Sene D, Schoindre Y, Lidove O, Le Hoang P, Hachulla E, Fain O, Mariette X, Papo T, Wechsler B, Bodaghi B, Rigon MR, Cacoub P, Saadoun D, French Behcet N (2015) Efficacy of anti-TNF alpha in severe and\/or refractory Behcet\u2019s disease: multicenter study of 124 patients. J Autoimmun 62:67\u201374. https:\/\/doi.org\/10.1016\/j.jaut.2015.06.005","journal-title":"J Autoimmun"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-023-05420-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-023-05420-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-023-05420-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T06:06:47Z","timestamp":1694412407000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-023-05420-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,17]]},"references-count":32,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["5420"],"URL":"https:\/\/doi.org\/10.1007\/s00296-023-05420-4","relation":{},"ISSN":["1437-160X"],"issn-type":[{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,17]]},"assertion":[{"value":"11 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"D.U has received honorariums for presentations from Abbvie and fees from Amgen as a consultant and advisory committee member. S.N.E has received honorariums for presentations from UCB Pharma, Roche, Pfizer and Merck Sharp Dohme. V.H. has received consultation fees from Abbvie, Novartis, Pfizer, and Roche. E.S. has received honorariums for presentations from Novartis, Pfizer, AbbVie and Gliead. G.H. has received research grant, lecture fees and fees for serving on an advisory board from Celgene, receiving consulting fees from UCB Pharma, Bayer, Johnson & Johnson, lecture fees from Novartis, Abbvie, Amgen, and UCB Pharma. No other disclosures were reported.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The ethics committee of Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty approved the study (2019\/150114). For this retrospective study informed consent is not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}